UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice

Human gene therapy, 2018-08, Vol.29 (8), p.861

2018

Link zum Volltext

Verfügbarkeit prüfen

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma

Cancer research (Chicago, Ill.), 2017-12, Vol.77 (24), p.6999-7013

2017

Link zum Volltext

Verfügbarkeit prüfen

CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses

Frontiers in immunology, 2022-08, Vol.13, p.909979-909979

2022

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

Clinical cancer research, 2006-04, Vol.12 (7), p.2197-2207

2006

Link zum Volltext

Verfügbarkeit prüfen

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

Clinical cancer research, 2006-11, Vol.12 (21), p.6573-6584

2006

Link zum Volltext

Verfügbarkeit prüfen

Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models

Neoplasia (New York, N.Y.), 2011, Vol.13 (1), p.49-59

2011

Link zum Volltext

Verfügbarkeit prüfen

The Fourth Intracellular Src Homology 3 Binding Motif of CD2 Is Required for Durable T Cell Activity

Corcoran, Erik

2023

Link zum Volltext
ProQuest

Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model

Antimicrobial Agents and Chemotherapy, 2008-01, Vol.52 (1), p.244-247

2008

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy?

Antimicrobial Agents and Chemotherapy, 2006-05, Vol.50 (5), p.1628-1632

2006

Link zum Volltext

Verfügbarkeit prüfen

Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models

Anticancer research, 2009-06, Vol.29 (6), p.1999-2007

2009

Link zum Volltext

Verfügbarkeit prüfen

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice

Cancer research (Chicago, Ill.), 2009-07, Vol.69 (14), p.5643-5647

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3641: Breaking through the ceiling: A program to significantly increase efficacy in KRAS and BRAF mutant colorectal cancer xenograft tumors whose growth is arrested by Cetuximab + irinotecan therapy

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3641-3641

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3126: H3B6527, a selective and potent FGFR4 inhibitor for FGF19-driven hepatocellular carcinoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3126-3126

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2932: SF3B1 mutations induce aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2932-2932

2014

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody IMC-EB10 and Methotrexate

Blood, 2008-11, Vol.112 (11), p.3964-3964

2008

Link zum Volltext

Verfügbarkeit prüfen

1-[4-(1 H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1 H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors

Bioorganic & medicinal chemistry letters, 2006-01, Vol.16 (2), p.409-412

2006

Link zum Volltext

Verfügbarkeit prüfen

In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida

Antimicrobial Agents and Chemotherapy, 2000-08, Vol.44 (8), p.2017-2022

2000

Link zum Volltext

Verfügbarkeit prüfen

Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models1

Neoplasia (New York, N.Y.), 2011-01, Vol.13 (1), p.49-59

2011

Link zum Volltext

Verfügbarkeit prüfen

In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2

Methods in molecular biology (Clifton, N.J.), 2009, Vol.525, p.545

2009

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

Antimicrobial agents and chemotherapy, 2000-08, Vol.44 (8), p.2017-2022

2000

Link zum Volltext

Verfügbarkeit prüfen

Tumor Necrosis Factor-α and lnterieukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

Cancer research (Chicago, Ill.), 2009, Vol.69 (14), p.5643-5647

2009

Link zum Volltext

Verfügbarkeit prüfen

Deliberate self-harm within an international community sample of young people: comparative findings from the Child & Adolescent Self-harm in Europe (CASE) Study

Journal of child psychology and psychiatry, 2008-06, Vol.49 (6), p.667-677

2008

Link zum Volltext

Verfügbarkeit prüfen

Trait drift in microalgae and applications for strain improvement

Biotechnology advances, 2022-11, Vol.60 (C), p.108034-108034, Article 108034

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(33)
Humans
(23)
Animals
(15)
Mice
(14)
Female
(13)
Biological And Medical Sciences
(11)
Male
(11)
Medical Sciences
(11)
Adolescent
(8)
Cell Line, Tumor
(8)
Disease Models, Animal
(8)
Oncology
(8)
Adult
(7)
Pharmacology. Drug Treatments
(7)
Mice, Nude
(6)
Antineoplastic Agents
(5)
General & Internal Medicine
(5)
Receptor, Epidermal Growth Factor - Antagonists & Inhibitors
(5)
Treatment Outcome
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma

CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses

Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models

The Fourth Intracellular Src Homology 3 Binding Motif of CD2 Is Required for Durable T Cell Activity

Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model

Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy?

Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice

Abstract 3641: Breaking through the ceiling: A program to significantly increase efficacy in KRAS and BRAF mutant colorectal cancer xenograft tumors whose growth is arrested by Cetuximab + irinotecan therapy

Abstract 3126: H3B6527, a selective and potent FGFR4 inhibitor for FGF19-driven hepatocellular carcinoma

Abstract 2932: SF3B1 mutations induce aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody IMC-EB10 and Methotrexate

Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation

1-[4-(1 H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1 H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors

In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida

Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models1

In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2

In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

Tumor Necrosis Factor-α and lnterieukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

Deliberate self-harm within an international community sample of young people: comparative findings from the Child & Adolescent Self-harm in Europe (CASE) Study

Trait drift in microalgae and applications for strain improvement

Suchergebnisse filtern